logo
This City Was Just Named the Healthiest Place to Live in the U.S. for 2025

This City Was Just Named the Healthiest Place to Live in the U.S. for 2025

Each year, Niche.com reveals the healthiest places in the nation, based on "a comprehensive assessment of the general health levels among residents in an area." The company considers key indicators of personal health, including smoking and excessive alcohol consumption, rates of obesity, and people's access and proximity to health care facilities, including gyms, doctors, and mental health practitioners.
And this year, Niche.com named Berkeley, California, the healthiest city in the U.S.
The Alameda County city is less than half an hour from San Francisco, and boasts 256 sunny days per year and a mild Mediterranean climate. Residents don't have to travel far to enjoy time in nature and stay active—Berkeley has over 50 parks with sports facilities, trails, and playgrounds. Additionally, places like Muir Woods National Monument, Yosemite National Park, and Pinnacles National Park offer even more options for outdoor recreation.
In fact, the city was named the No. 1 Healthiest Place to Live in America and the No. 1 Healthiest City, really driving home the point that this is indeed a healthy place. Berkeley also snagged an A+ rating for its schools, A+ for nightlife, and an A+ for outdoor activities, which surely helps to keep its population in tip-top shape. The only categories it falls short in are housing, where it scored a C-, crime and safety, which also nabbed it a C-, and the cost of living, where it scored a low D+. And these grades are well reflected in the local reviews.
"Berkeley is a totally unique city. I have never seen another place so littered with diversity. There are all kinds of people from all walks of life, and there is no place as notorious as Berkeley for self-expression," one person shared on Niche.com. "Life is technically not great here, with expensive and rare housing opportunities and a struggling job market, but for all aspects of life where life is actually supposed to be fun, Berkeley thrives."
But this isn't the only place people can feel that healthy buzz. Cambridge, Massachusetts, ranked second, followed by Irvine, California, Bellevue, Washington, and Seattle, Washington, rounding out the top five healthiest cities in the country.
You can see where your city ranks and read the complete list at niche.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Firefighters save San Diego apartments from patio fire
Firefighters save San Diego apartments from patio fire

Yahoo

time27 minutes ago

  • Yahoo

Firefighters save San Diego apartments from patio fire

SAN DIEGO (FOX 5/KUSI) — Firefighters were able to save an apartment complex from catching fire after several nearby patios went up in flames in San Diego Saturday evening. San Diego Fire-Rescue firefighters arrived to find several patios on fire at an apartment building in the 4300 block of Altadena Avenue in the Colina Del Sol neighborhood just after 5 p.m. Saturday. Car flips in Santee, striking fire hydrant and causing 50-foot geyser An SDFD battalion chief said the fire started when some residents were cooking on their patio and it grew, engulfing several other patios and a fence, threatening a nearby larger apartment complex. Firefighters arrived on the scene quickly and sprayed fire lines between the apartment complexes, stopping the fire from spreading to the neighboring complex, according to SDFD. All residents were evacuated before first responders arrived, SDFD said. However, one person was taken to the hospital for smoke inhalation. Firefighters stayed at the scene for a short time Saturday after they put out the fire to inspect the building and check for any sign of fire in the attic. In total, 32 San Diego Fire-Rescue personnel battled the fire, which was fully put out by 7 p.m. Saturday. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data
Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data

Yahoo

time42 minutes ago

  • Yahoo

Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its 'Buy' rating on Iovance's stock on June 3. The firm also maintained its $34.00 price target for Iovance shares. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. Goldman Sachs based its reaffirmation on new data that Iovance presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO data focused on Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy. The FDA approved the treatment in February 2024 for adult patients with unresectable or metastatic melanoma. The data supported the therapy's safety profile, which, according to Goldman Sachs, reinforces Amtagvi's potential as a significant treatment option. Goldman Sachs's analysts noted that the five-year follow-up data are unprecedented for any therapy in this heavily pretreated advanced melanoma population. To them, the data highlights the durability of Amtagvi's responses. The firm emphasized Amtagvi's successful US launch, with consistent patient demand, enhanced operations at Authorized Treatment Centers (ATCs), and improved out-of-spec rates (manufacturing quality metrics). It also highlighted the drug's first full calendar year of sales in 2025 as a key driver. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company. It develops and markets cell therapies that harness a patient's own immune cells to treat solid tumors. Its lead product is Amtagvi, approved for advanced melanoma, and it also markets Proleukin. Iovance's pipeline includes candidates for cervical cancer, non-small cell lung cancer, and hematologic malignancies. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Yahoo

time42 minutes ago

  • Yahoo

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store